Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

Phase 2

Terminated

• Conditions: Brain Neoplasms; Non Small Cell Lung Cancer

• Registration Number: NCT00234442
• Lead Sponsor: AstraZeneca

Brief Summary

The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC

Detailed Description

Not available

Study Timeline

• Study Start: 2004-07
• Study First Submitted: 2005-10-05
• Study First Submitted QC: 2005-10-05
• Study First Posted: 2005-10-07
• Study Completion: 2006-02
• Status Verified: 2009-06
• Last Update Submitted: 2009-06-29
• Last Update Posted: 2009-06-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

• Radiologically confirmed brain metastases from Non Small Cell Lung Cancer
• No symptoms due to brain metastases
• No previous radiotherapy treatment for the Brain metastases

Exclusion Criteria

• No prior chemotherapy
• No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
• Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Disease control rate (complete response, partial response and stable disease)

Secondary Outcome Measures

Name	Time	Method
Duration of response
Time to progression
Overall Survival

Trial Locations

Locations (1)

Research Site; 🇮🇹 Rozzano, Italy